title: Application of oncoproteomics to aberrant signalling networks in changing the treatment paradigm in acute lymphoblastic leukaemia.
abstract: Oncoproteomics is an important innovation in the early diagnosis, management and development of personalized treatment of acute lymphoblastic leukaemia (ALL). As inherent factors are not completely known - e.g. age or family history, radiation exposure, benzene chemical exposure, certain viral exposures such as infection with the human T-cell lymphoma/leukaemia virus-1, as well as some inherited syndromes may raise the risk of ALL - each ALL patient may modify the susceptibility of therapy. Indeed, we consider these unknown inherent factors could be explained via coupling cytogenetics plus proteomics, especially when proteins are the ones which play function within cells. Innovative proteomics to ALL therapy may help to understand the mechanism of drug resistance and toxicities, which in turn will provide some leads to improve ALL management. Most important of these are shotgun proteomic strategies to unravel ALL aberrant signalling networks. Some shotgun proteomic innovations and bioinformatic tools for ALL therapies will be discussed. As network proteins are distinctive characteristics for ALL patients, unrevealed by cytogenetics, those network proteins are currently an important source of novel therapeutic targets that emerge from shotgun proteomics. Indeed, ALL evolution can be studied for each individual patient via oncoproteomics.
authors.affiliation: Department of Oncohematology and Pediatrics, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: López Villar
authors.forename: Xiangdong
authors.initials: X
authors.lastname: Wang
authors.forename: Luis
authors.initials: L
authors.lastname: Madero
authors.forename: William C
authors.initials: WC
authors.lastname: Cho
mesh_terms: D019295:Computational Biology; D006801:Humans; D057285:Precision Medicine; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000378:metabolism* / Q000628:therapy*; D040901:Proteomics / Q000379:methods*; D015398:Signal Transduction; D014178:Translocation, Genetic
keywords: acute lymphoblastic leukaemia; personalized medicine; shotgun proteomics